8-K: Avalo Therapeutics' AVTX-009 IND Active, Phase 2 Trial for Hidradenitis Suppurativa to Commence

Avalo Therapeutics has announced that the Investigational New Drug (IND) application for AVTX-009, an anti-IL-1 monoclonal antibody, is now active, allowing the company to proceed with its Phase 2 clinical trial for hidradenitis suppurativa.

Summary

• Avalo Therapeutics has received an active Investigational New Drug (IND) status for AVTX-009, an anti-IL-1 monoclonal antibody.
• This allows Avalo to begin its Phase 2 LOTUS clinical trial to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa (HS).
• The Phase 2 trial is a randomized, double-blind, placebo-controlled study with two AVTX-009 dose regimens.
• Approximately 180 adults with moderate to severe HS will be enrolled in the trial.
• The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16.
• The first patient is expected to be enrolled in the Phase 2 LOTUS Trial this year.
• Avalo acquired the product candidate in late March 2024 and achieved this milestone in just over three months.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful activation of the IND and the commencement of the Phase 2 trial. The management's confidence in the potential of AVTX-009 also contributes to the positive outlook.

Positives

• The active IND status for AVTX-009 is a significant step forward for Avalo's clinical development program.
• The rapid progress from acquisition to active IND in just over three months demonstrates the company's efficiency.
• AVTX-009 is believed to have the potential to be best-in-class and best-in-indication due to its target, half-life, and potency.
• The Phase 2 trial design is robust, using a randomized, double-blind, placebo-controlled approach.
• The trial will evaluate two different dose regimens of AVTX-009, which could provide valuable data on optimal dosing.

Risks

• The success of the Phase 2 trial is not guaranteed, and results may not meet expectations.
• There are risks associated with patient enrollment and retention in clinical trials.
• Regulatory risks and potential delays in the approval process could impact the timeline for commercialization.
• The company is subject to general economic and market risks, including those caused by geopolitical events.
• There are risks associated with the integration of AVTX-009 into Avalo's operations.

Future Outlook

Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year and is focused on advancing the clinical development of AVTX-009.

Management Comments

• Dr. Garry Neil, Chief Executive Officer and Chairman of the Board, stated that the active IND is an important step for commencing the LOTUS trial.
• Dr. Neil also expressed pride in the Avalo team for achieving this milestone in just over three months from acquiring the product candidate.
• Management believes that AVTX-009 has the potential to be best-in-class and best-in-indication due to its target, half-life, and potency.

Industry Context

This announcement is significant in the context of the limited treatment options available for hidradenitis suppurativa, a chronic inflammatory skin condition. The development of AVTX-009, an anti-IL-1 monoclonal antibody, aligns with the growing focus on targeted therapies for inflammatory diseases.

Comparison to Industry Standards

• The development of monoclonal antibodies targeting IL-1 is a recognized approach in the treatment of inflammatory diseases, with companies like Novartis (Canakinumab) and Regeneron (Arcalyst) having similar products on the market.
• The Phase 2 trial design for AVTX-009, using a randomized, double-blind, placebo-controlled approach, is consistent with industry standards for clinical trials.
• The primary endpoint of HiSCR75 at Week 16 is a commonly used measure in hidradenitis suppurativa trials, allowing for comparison with other treatments.
• The enrollment target of approximately 180 patients is a reasonable size for a Phase 2 trial in this indication.

Stakeholder Impact

• Shareholders will likely view the active IND status and commencement of the Phase 2 trial as positive developments.
• Patients with hidradenitis suppurativa may benefit from the development of a new treatment option.
• Employees of Avalo will be involved in the execution of the clinical trial.
• The company's suppliers and partners may see increased activity related to the trial.

Next Steps

• Avalo will commence the Phase 2 LOTUS clinical trial for AVTX-009.
• The company expects to enroll the first patient in the Phase 2 LOTUS Trial this year.
• Avalo will continue to monitor the progress of the trial and report results as they become available.

Key Dates

Keywords

AVTX-009, Hidradenitis Suppurativa, Monoclonal Antibody, Anti-IL-1, Phase 2 Trial, Clinical Trial, LOTUS Trial, IND, Avalo Therapeutics, Inflammatory Disease